Disease modifying agents capable of controlling obesity with meaningful metabolic improvement have reshaped expectations for both clinicians and patients ( Nausea and vomiting remain among the most frequent and disruptive adverse effects across Glucagon-like peptide (GLP-1)-based therapies ( In this opinion article, we examine the mechanisms underlying nausea and vomiting in semaglutide, CagriSema, survodutide, tirzepatide, retatrutide, and orforglipron and situate them within obesity clinical practice ( We also propose practical strategies to mitigate gastrointestinal intolerance
After an adaptation period of 3 days inside the CLAMS, these metabolic parameters were evaluated for 4 consecutive days
In the future, the identification of specific genes or pathways could serve as direct targets, in conjunction with cysteine deprivation for cancer therapy
Matek, D., Matek, I., Staresinic, E., Japjec, M., Bojanic, I., Blagaic, A